Table 2.
Characteristics of patients with and without AIHA
| Characteristic | Patients with AIHA | Patients without AIHA | P |
|---|---|---|---|
| Gender, n (%) | .457 | ||
| Male | 15 (58) | 737 (55) | |
| Female | 11 (42) | 614 (45) | |
| Median age at HSCT, y (range) | 23.5 (15‐46) | 30 (13‐78) | .466 |
| Type of underlying disease, n (%) | .318 | ||
| Myelogenous | 12(46) | 770 (57) | |
| Lymphoid | 14 (54) | 581 (43) | |
| Disease status at HSCT, n (%) | .741 | ||
| CR | 18 (69) | 975 (72) | |
| Non‐CR | 8 (31) | 376 (28) | |
| Donor source, n (%) | <.001* | ||
| MSD | 6 (23) | 760 (56) | |
| MUD | 5 (19) | 323 (24) | |
| HRD | 15 (58) | 268 (20) | |
| HLA disparity, n (%) | <.001* | ||
| Matched | 11 (42) | 1045 (77) | |
| Mismatched | 15 (58) | 306 (23) | |
| ABO matched, n (%) | .985 | ||
| Yes | 13 (50) | 678 (50) | |
| No | 13 (50) | 673 (50) | |
| Sex matched, n (%) | .232 | ||
| Yes | 15 (58) | 620 (46) | |
| No | 11 (42) | 731 (54) | |
| Conditioning regimens, n (%) | .443 | ||
| TBI used | 17 (65) | 782 (58) | |
| TBI non‐used | 9 (35) | 569 (42) | |
| GVHD prophylaxis, n (%) | .001* | ||
| ATG used | 21 (81) | 651 (48) | |
| ATG non‐used | 5 (19) | 700 (52) | |
| Source of stem cell, n (%) | <.001* | ||
| Bone marrow + PBSCs | 15 (58) | 294 (22) | |
| PBSCs | 11 (42) | 1057 (78) | |
| CMV viremia posttransplants, n (%) | .991 | ||
| Yes | 14 (54) | 726 (54) | |
| No | 12 (46) | 625 (46) | |
| aGVHD, n (%) | .711 | ||
| Yes | 11 (42) | 621 (46) | |
| No | 15 (58) | 730 (54) | |
| cGVHD, n (%) | .009* | ||
| Yes | 18 (69) | 582 (43) | |
| No | 8 (31) | 769 (57) |
Abbreviations: aGVHD, acute graft vs host disease; AIHA, autoimmune hematological diseases; ATG, antithymocyte globulin; cGVHD, chronic graft vs host disease; CMV, cytomegalovirus; CR, complete remission; GVHD, graft vs host disease; HLA, human leukocyte antigen; HRD, haploidentical‐related donor; HSCT, hematopoietic stem cell transplantation; MSD, matched sibling donor; MUD, matched unrelated donor; TBI, total body irradiation; PBSCs, peripheral blood stem cells.
*
P < .05.